Lack of efficacy of rituximab in Felty's syndrome

Annals of the Rheumatic Diseases

Volumn 64, Issue 2, 2005, Pages 332-333

  Sordet, C ^a   Gottenberg, J E ^a   Hellmich, B ^a   Kieffer, P ^a   Mariette, X ^a   Sibilia, J ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; METHOTREXATE; RITUXIMAB; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DRUG EFFICACY; FELTY SYNDROME; HUMAN; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FELTY'S SYNDROME; HUMANS; MALE; MIDDLE AGED; TREATMENT FAILURE;

EID: 13244292643     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.025643     Document Type: Article

References (5)

1. Hellmich B, Csernok E, Schatz H, Gross WL, Schnabel A. Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum 2002;46:2384-91.
2. Rashba EJ, Rowe JM, Packman CH. Treatment of the neutropenia of Felty syndrome. Blood Rev 1996;10:177-84.
3. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48:1484-92.
4. Papadaki T, Stamatopoulos K, Anagnostopoulos A, Fassas A. Rituximab-associated immune myelopathy. Blood 2003;102:1557-8.
5. Coakley G, Iqbal M, Brooks D, Panayi GS, Lanchbury JJ. CD8+ CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty's and large granular lymphocyte syndrome. Arthritis Rheum 2000;43:834-43.